# GeneBioHealth

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genebiohealth

- Industry: Medical Devices & Equipment
- Headquarters: Shenzhen, China
- Website: www.genebiohealth.com
- Total disclosed funding: $15M
- Latest round: Series B (Oct 18, 2022)
- Investors on record: 1

## About

Based in Shenzhen, China and founded in 2013, GeneBioHealth operates as a diagnostic reagent developer that focuses on in vitro diagnostics (IVD) and healthcare. The company headquarter in Shenzhen has 1500 square meters. And has over 500 square meters of GMP standard workshop. Haoyang Yu is the founder of the company, once served as project manager of R&D and quality safety headquarters of Bayer Pharmaceutical Co., Ltd. In January 2017, GeneBioHealth passed the ISO13485 certification. In March 2018, GeneBioHealth's product - Ruichangtai ® MiR-92a test kit was approved for listing.

Its products include tumor diagnosis, Covid-19 protection, immunodiagnosis (POCT) and instrument. Covid-19 protection includes SARS-CoV-2 IgM/IgG test kit(colloidal gold), SARS-COV-2 nucleic acid test kit (RT-PCR) and Baihuikang hypochlorous acid disinfectant. POCT includes the testing of cardiovascular, inflammatory and digestive function. The company's services include detection of tumor, membership service, detection report and health file.

## Funding rounds

- Series B, Oct 18, 2022, $15M — Yuecai Zhongyin Private Equity

## Investors

- Yuecai Zhongyin Private Equity (https://capitalatlas.ai/funds/yuecai-zhongyin-private-equity) — Series B